Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Cerenis Lead Candidate Fails Phase II Study in ACS

Cerenis Therapeutics acknowledged today that its lead candidate CER-001 has failed a Phase II clinical trial assessing the drug ...

Forward this item to a colleague:

(Separate multiple addresses by commas)